Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05980169 · ClinicalTrials.gov registry record · NA
The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy
A NA study of Gynecologic Cancer and Neuropathy;Peripheral, sponsored by Augusta University.
- Active
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05980169: Active NA study of Gynecologic Cancer and Neuropathy;Peripheral, sponsored by Augusta University.
NCT05980169 is a NA study of Gynecologic Cancer and Neuropathy;Peripheral that is active but no longer recruiting, run by Augusta University. The registered enrollment target is 80 participants, below the 763-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05980169, a NA study of Gynecologic Cancer and Neuropathy;Peripheral, is active but no longer recruiting, sponsored by Augusta University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess the efficacy of SensoniQ® Treatment Station in preventing or reducing chemotherapy induced peripheral neuropathy symptoms (CIPNS) in patients receiving frontline carboplatin and paclitaxel chemotherapy for a gynecologic malignancy. This study will also assess the improvement of CIPNS in patients who have previously received carboplatin and paclitaxel therapy with persistent Grade 2 or worse neuropathy. The main questions this clinical trial aims to answer are: 1. To investigate the efficacy of SensoniQ® Treatment Station on the prevention or reduction of CIPNS in gynecologic oncology patients receiving front line carboplatin and paclitaxel. 2. To investigate the efficacy of SensoniQ® Treatment Station on the improvement of existing CIPNS in patients who previously received chemotherapy with platinum agent and paclitaxel for a gynecologic malignancy
Primary Outcome
Percent of patients reporting neuropathy based on post treatment Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Questionnaire (FACT/GOG NTX) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN Twenty Item Subscale (EORTC QLQ-CIPN20) scores (This primary outcome is specific to Cohort A)
Conditions Studied
Interventions
- DEVICE SensoniQ Treatment Station
Study Locations (1)
Georgia
- James T Sonnenberg - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-11-29 |
| Est. Completion | 2029-12-01 |
| Phase | NA |
What the registry record for NCT05980169 still lists
NCT05980169 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 763-participant average among 55 other Gynecologic Cancer trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Gynecologic Cancer appearing as the primary indexed condition, and to 1 intervention - of which SensoniQ Treatment Station is the first listed.
NCT05980169 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05980169 about?
NCT05980169 is a clinical study titled "The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy". The goal of this clinical trial is to assess the efficacy of SensoniQ® Treatment Station in preventing or reducing chemotherapy induced peripheral neuropathy symptoms (CIPNS) in patients receiving frontline carboplatin and paclitaxel chemotherapy for a gynecologic malignancy. This study will also as...
What is the current status of trial NCT05980169?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2023-11-29. Estimated completion is 2029-12-01.
What conditions does trial NCT05980169 study?
This clinical trial studies the following conditions: Gynecologic Cancer, Neuropathy;Peripheral.
What interventions are being tested in trial NCT05980169?
The interventions under investigation include: SensoniQ Treatment Station (DEVICE).
Who is sponsoring clinical trial NCT05980169?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05980169 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gynecologic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05980169's enrollment target sits among peer trials
80 25th of 55 higher than 31 of 55 other Gynecologic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gynecologic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
RECRUITING · NA
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Activity Coaching During Pelvic Radiation Therapy
RECRUITING · NA
-
Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI